: Under the terms of the merger agreement, all outstanding shares of ASXC were acquired for $0.35 per share in cash .

: KARL STORZ acquired the company primarily for its Senhance Surgical System and the development of the next-generation LUNA™ System , aiming to integrate these into their global endoscopy portfolio.

: On August 22, 2024, KARL STORZ finalized its acquisition of Asensus Surgical.

AI responses may include mistakes. For financial advice, consult a professional. Learn more

: The symbol transitioned from TRXC to ASXC as part of this corporate shift.